[1]
|
Minna, J.D., Roth, J.A. and Gazdar, A.F. (2002) Focus on Lung Cancer. Cancer Cell, 1, 49-52. https://doi.org/10.1016/S1535-6108(02)00027-2
|
[2]
|
Travis, W.D. (2020) Lung Cancer Pathology: Current Concepts. Clinics in Chest Medicine, 41, 67-85. https://doi.org/10.1016/j.ccm.2019.11.001
|
[3]
|
Thandra, K.C., Barsouk, A., Saginala, K., Aluru, J.S. and Barsouk, A. (2021) Epidemiology of Lung Cancer. Contemporary Oncology, 25, 45-52. https://doi.org/10.5114/wo.2021.103829
|
[4]
|
Zhao, Y., Liu, Y., Li, S., Peng, Z., Liu, X., Chen, J. and Zheng, X. (2021) Role of Lung and Gut Microbiota on Lung Cancer Pathogenesis. Journal of Cancer Research and Clinical Oncology, 147, 2177-2186. https://doi.org/10.1007/s00432-021-03644-0
|
[5]
|
Khan, S.A., Goliwas, K.F. and Deshane, J.S. (2021) Sphingolipids in Lung Pathology in the Coronavirus Disease Era: A Review of Sphingolipid Involvement in the Pathogenesis of Lung Damage. Frontiers in Physiology, 12, Article 760638. https://doi.org/10.3389/fphys.2021.760638
|
[6]
|
Chen, Y.-J., Roumeliotis, T.I., Chang, Y.-H., Chen, C.-T., Han, C.-L., et al. (2020) Proteogenomics of Non-Smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression. Cell, 182, 226-244. https://doi.org/10.1016/j.cell.2020.06.012
|
[7]
|
Vinod, S.K. and Hau, E. (2020) Radiotherapy Treatment for Lung Cancer: Current Status and Future Directions. Respirology, 25, 61-71. https://doi.org/10.1111/resp.13870
|
[8]
|
Carrasco-Esteban, E., Domínguez-Rullán, J.A., Barrionuevo-Castillo, P., Pelari-Mici, L., Leaman, O., Sastre-Gallego, S. and López-Campos, F. (2021) Current Role of Nanoparticles in the Treatment of Lung Cancer. Journal of Clinical and Translational Research, 7, 140-155.
|
[9]
|
Su, X.-L., Wang, J.-W., Che, H., Wang, C.-F., Jiang, H., Lei, X., Zhao, W., Kuang, H.-X. and Wang, Q.-H. (2020) Clinical Application and Mechanism of Traditional Chinese Medicine in Treatment of Lung Cancer. Chinese Medical Journal, 133, 2987-2997. https://doi.org/10.1097/CM9.0000000000001141
|
[10]
|
Guibert, N., Pradines, A., Favre, G. and Mazieres, J. (2020) Current and Future Applications of Liquid Biopsy in Nonsmall Cell Lung Cancer from Early to Advanced Stages. European Respiratory Review, 29, Article 190052. https://doi.org/10.1183/16000617.0052-2019
|
[11]
|
Xiang, Y., Huang, C., He, Y. and Zhang, Q. (2021) Cancer or Tuberculosis: A Comprehensive Review of the Clinical and Imaging Features in Diagnosis of the Confusing Mass. Frontiers in Oncology, 11, Article 644150. https://doi.org/10.3389/fonc.2021.644150
|
[12]
|
Zhu, T., Bao, X., Chen, M., Lin, R., Zhuyan, J.N., Zhen, T., Xing, K., Zhou, W. and Zhu, S. (2020) Mechanisms and Future of Non-Small Cell Lung Cancer Metastasis. Frontiers in Oncology, 10, Article 585284. https://doi.org/10.3389/fonc.2020.585284
|
[13]
|
Shiravand, Y., Khodadadi, F., Kashani, S.M.A., Hosseini-Fard, S.R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K. and Kulasinghe, A. (2022) Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology, 29, 3044-3060. https://doi.org/10.3390/curroncol29050247
|
[14]
|
Vafaei, S., Zekiy, A.O., Khanamir, R.A., Zaman, B.A., Ghayourvahdat, A., Azimizonuzi, H. and Zamani, M. (2022) Combination Therapy with Immune Checkpoint Inhibitors (ICIs); a New Frontier. Cancer Cell International, 22, Article No. 2. https://doi.org/10.1186/s12935-021-02407-8
|
[15]
|
Robert, C. (2020) A Decade of Immune-Checkpoint Inhibitors in Cancer Therapy. Nature Communications, 11, Article No. 3801. https://doi.org/10.1038/s41467-020-17670-y
|
[16]
|
Singh, S., Hassan, D., Aldawsari, H.M., Molugulu, N., Shukla, R. and Kesharwani, P. (2020) Immune Checkpoint Inhibitors: A Promising Anticancer Therapy. Drug Discovery Today, 25, 223-229. https://doi.org/10.1016/j.drudis.2019.11.003
|
[17]
|
Sondak, V.K., Smalley, K.S., Kudchadkar, R., Grippon, S. and Kirkpatrick, P. (2011) Ipilimumab. Nature Reviews Drug Discovery, 10, 411-412. https://doi.org/10.1038/nrd3463
|
[18]
|
Hodi, F.S., O’day, S.J., Mcdermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D. and Hassel, J.C. (2010) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine, 363, 711-723. https://doi.org/10.1056/NEJMoa1003466
|
[19]
|
Wolchok, J.D., Hodi, F.S., Weber, J.S., Allison, J.P., Urba, W.J., Robert, C., O’day, S.J., Hoos, A., Humphrey, R. and Berman, D.M. (2013) Development of Ipilimumab: A Novel Immunotherapeutic Approach for the Treatment of Advanced Melanoma. Annals of the New York Academy of Sciences, 1291, 1-13. https://doi.org/10.1111/nyas.12180
|
[20]
|
Paz-Ares, L.G., Ramalingam, S.S., Ciuleanu, T.-E., Lee, J.-S., Urban, L., Caro, R.B., Park, K., Sakai, H., Ohe, Y. and Nishio, M. (2022) First-Line Nivolumab plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes from the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. Journal of Thoracic Oncology, 17, 289-308. https://doi.org/10.1016/j.jtho.2021.09.010
|
[21]
|
Pinto, J.A., Raez, L.E., Oliveres, H. and Rolfo, C.C. (2019) Current Knowledge of Ipilimumab and Its Use in Treating Non-Small Cell Lung Cancer. Expert Opinion on Biological Therapy, 19, 509-515. https://doi.org/10.1080/14712598.2019.1610380
|
[22]
|
Hellmann, M.D., Paz-Ares, L., Caro, R.B., Zurawski, B., Kim, S.-W., Costa, E.C., Park, K., et al. (2019) Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer. New England Journal of Medicine, 381, 2020-2031. https://doi.org/10.1056/NEJMoa1910231
|
[23]
|
Gunturi, A. and Mcdermott, D.F. (2015) Nivolumab for the Treatment of Cancer. Expert Opinion on Investigational Drugs, 24, 253-60. https://doi.org/10.1517/13543784.2015.991819
|
[24]
|
Khoja, L., Butler, M.O., Kang, S.P., Ebbinghaus, S. and Joshua, A.M. (2015) Pembrolizumab. Journal for Immunotherapy of Cancer, 3, 1-13. https://doi.org/10.1186/s40425-015-0078-9
|
[25]
|
Wang, C., Thudium, K.B., Han, M., Wang, X.-T., Huang, H., Feingersh, D., Garcia, C., Wu, Y., Kuhne, M. and Srinivasan, M. (2014) in Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and in Vivo Toxicology in Non-Human Primates. Cancer Immunology Research, 2, 846-856. https://doi.org/10.1158/2326-6066.CIR-14-0040
|
[26]
|
Borghaei, H., Gettinger, S., Vokes, E.E., Chow, L.Q., Burgio, M.A., de Castro Carpeno, J., Pluzanski, A., Arrieta, O., Frontera, O.A. and Chiari, R. (2021) Five-Year Outcomes from the Randomized, Phase III Trials Checkmate 017 and 057: Nivolumab versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 39, 723-733. https://doi.org/10.1200/JCO.20.01605
|
[27]
|
Horn, L., Spigel, D.R., Vokes, E.E., Holgado, E., Ready, N., Steins, M., Poddubskaya, E., Borghaei, H., Felip, E. and Paz-Ares, L. (2017) Nivolumab versus Docetaxel in Previously Treated Patients with Advanced Non0-Small-Cell Lung Cancer: Two-Year Outcomes from Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). Journal of Clinical Oncology, 35, 3924-3933. https://doi.org/10.1200/JCO.2017.74.3062
|
[28]
|
Brahmer, J.R., Lee, J.-S., Ciuleanu, T.-E., Bernabe, Caro, R., Nishio, M., Urban, L., Audigier-Valette, C., Lupinacci, L., Sangha, R. and Pluzanski, A. (2023) Five-Year Survival Outcomes with Nivolumab plus Ipilimumab versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. Journal of Clinical Oncology, 41, 1200-1212. https://doi.org/10.1200/JCO.22.01503
|
[29]
|
Li, J., Xuan, S., Dong, P., Xiang, Z., Gao, C., Li, M., Huang, L. and Wu, J. (2023) Immunotherapy of Hepatocellular Carcinoma: Recent Progress and New Strategy. Frontiers in Immunology, 14, Article 1192506. https://doi.org/10.3389/fimmu.2023.1192506
|
[30]
|
Leighl, N.B., Hellmann, M.D., Hui, R., Carcereny, E., Felip, E., Ahn, M.-J., Eder, J.P., Balmanoukian, A.S., Aggarwal, C. and Horn, L. (2019) Pembrolizumab in Patients with Advanced Non-Small-Cell Lung Cancer (KEYNOTE-001): 3-Year Results from an Open-Label, Phase 1 Study. The Lancet Respiratory Medicine, 7, 347-357. https://doi.org/10.1016/S2213-2600(18)30500-9
|
[31]
|
Herbst, R.S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J.L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C.D. and Ahn, M.-J. (2016) Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. The Lancet, 387, 1540-1550. https://doi.org/10.1016/S0140-6736(15)01281-7
|
[32]
|
Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., et al. (2019) Updated Analysis of KEYNOTE-024: Pembrolizumab versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score of 50% or Greater. Journal of Clinical Oncology, 37, 537-546. https://doi.org/10.1200/JCO.18.00149
|
[33]
|
Mok, T.S., Wu, Y.-L., Kudaba, I., Kowalski, D.M., Cho, B.C., Turna, H.Z., Castro, G., Srimuninnimit, V., Laktionov, K.K. and Bondarenko, I. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830. https://doi.org/10.1016/S0140-6736(18)32409-7
|
[34]
|
Gadgeel, S., Rodriguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M.J., Clingan, P. and Powell, S.F. (2020) Updated Analysis from KEYNOTE-189: Pembrolizumab or Placebo plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 38, 1505-1517. https://doi.org/10.1200/JCO.19.03136
|
[35]
|
Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Parra, H.S., Mazières, J., et al. (2020) A Randomized, Placebo-Controlled Trial of Pembrolizumab plus Chemotherapy in Patients with Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. Journal of Thoracic Oncology, 15, 1657-1669. https://doi.org/10.1016/j.jtho.2020.06.015
|
[36]
|
Sunshine, J. and Taube, J.M. (2015) Pd-1/Pd-L1 Inhibitors. Current Opinion in Pharmacology, 23, 32-38. https://doi.org/10.1016/j.coph.2015.05.011
|
[37]
|
Doroshow, D.B., Bhalla, S., Beasley, M.B., Sholl, L.M., Kerr, K.M., Gnjatic, S., Wistuba, I.I., Rimm, D.L., Tsao, M.S. and Hirsch, F.R. (2021) PD-L1 as a Biomarker of Response to Immune-Checkpoint Inhibitors. Nature Reviews Clinical Oncology, 18, 345-362. https://doi.org/10.1038/s41571-021-00473-5
|
[38]
|
Socinski, M.A., Jotte, R.M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodr, Guez-Abreu, D., Moro-Sibilot, D., Thomas, C.A. and Barlesi, F. (2018) Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New England Journal of Medicine, 378, 2288-2301. https://doi.org/10.1056/NEJMoa1716948
|
[39]
|
Horn, L., Mansfield, A.S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M.J., Huemer, F., Losonczy, G., Johnson, M.L. and Nishio, M. (2018) First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine, 379, 2220-2229. https://doi.org/10.1056/NEJMoa1809064
|
[40]
|
Finn, R.S., Qin, S., Ikeda, M., Galle, P.R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P. and Kaseb, A.O. (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 382, 1894-1905. https://doi.org/10.1056/NEJMoa1915745
|
[41]
|
Liu, W., Huo, G. and Chen, P. (2022) Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. Frontiers in Immunology, 13, Article 909027. https://doi.org/10.3389/fimmu.2022.909027
|
[42]
|
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., Von, Pawel, J., Gadgeel, S.M., Hida, T., Kowalski, D.M. and Dols, M.C. (2017) Atezolizumab versus Docetaxel in Patients with Previously Treated Non-Small-Cell Lung Cancer (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial. The Lancet, 389, 255-265. https://doi.org/10.1016/S0140-6736(16)32517-X
|
[43]
|
Reck, M., Mok, T.S., Nishio, M., Jotte, R.M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodr, Guez-Abreu, D. and Moro-Sibilot, D. (2019) Atezolizumab plus Bevacizumab and Chemotherapy in Non-Small-Cell Lung Cancer (IMpower150): Key Subgroup Analyses of Patients with EGFR Mutations or Baseline Liver Metastases in a Randomised, Open-Label Phase 3 Trial. The Lancet Respiratory Medicine, 7, 387-401. https://doi.org/10.1016/S2213-2600(19)30084-0
|
[44]
|
Liu, S.V., Reck, M., Mansfield, A.S., Mok, T., Scherpereel, A., Reinmuth, N., Garassino, M.C., De Castro Carpeno, J., Califano, R. and Nishio, M. (2021) Updated Overall Survival and PD-L1 Subgroup Analysis of Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Atezolizumab, Carboplatin, and Etoposide (IMpower133). Journal of Clinical Oncology, 39, 619-630. https://doi.org/10.1200/JCO.20.01055
|
[45]
|
Alvarez-Argote, J. and Dasanu, C.A. (2019) Durvalumab in Cancer Medicine: A Comprehensive Review. Expert Opinion on Biological Therapy, 19, 927-935. https://doi.org/10.1080/14712598.2019.1635115
|
[46]
|
Antonia, S.J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K.H., et al. (2017) Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. New England Journal of Medicine, 377, 1919-1929. https://doi.org/10.1056/NEJMoa1709937
|
[47]
|
Spigel, D.R., Faivre-Finn, C., Gray, J.E., Vicente, D., Planchard, D., Paz-Ares, L., Vansteenkiste, J.F., Garassino, M.C., Hui, R. and Quantin, X. (2022) Five-Year Survival Outcomes from the PACIFIC Trial: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 40, 1301-1311. https://doi.org/10.1200/JCO.21.01308
|
[48]
|
Bang, A., Schoenfeld, J.D. and Sun, A.Y. (2019) PACIFIC: Shifting Tides in the Treatment of Locally Advanced Non-Small Cell Lung Cancer. Translational Lung Cancer Research, 8, S139-S146. https://doi.org/10.21037/tlcr.2019.09.04
|
[49]
|
Shen, X. and Zhao, B. (2018) Efficacy of PD-1 or PD-L1 Inhibitors and PD-L1 Expression Status in Cancer: Meta-Analysis. British Medical Journal, 362, k3529. https://doi.org/10.1136/bmj.k3529
|
[50]
|
Pillai, R.N., Behera, M., Owonikoko, T.K., Kamphorst, A.O., Pakkala, S., Belani, C.P., Khuri, F.R., Ahmed, R. and Ramalingam, S.S. (2018) Comparison of the Toxicity Profile of PD‐1 versus PD‐L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature. Cancer, 124, 271-277. https://doi.org/10.1002/cncr.31043
|
[51]
|
Spagnuolo, A. and Gridelli, C. (2018) “Comparison of the Toxicity Profile of PD-1 versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer”: Is There a Substantial Difference or Not? Journal of Thoracic Disease, 10, S4065. https://doi.org/10.21037/jtd.2018.09.83
|
[52]
|
Sacher, A.G. and Gandhi, L. (2016) Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. JAMA Oncology, 2, 1217-1222. https://doi.org/10.1001/jamaoncol.2016.0639
|
[53]
|
Hamid, O., Robert, C., Daud, A., Hodi, F., Hwu, W., Kefford, R., Wolchok, J., Hersey, P., Joseph, R. and Weber, J. (2019) Five-Year Survival Outcomes for Patients with Advanced Melanoma Treated with Pembrolizumab in KEYNOTE-001. Annals of Oncology, 30, 582-588. https://doi.org/10.1093/annonc/mdz011
|